Structures by: Essassi E. M.
Total: 358
4-Benzylsulfanyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C12H10N4S
Acta Crystallographica Section E (2013) 69, 11 o1650
a=9.4737(3)Å b=5.1709(2)Å c=23.6159(8)Å
α=90.00° β=96.8230(10)° γ=90.00°
1-Octylindoline-2,3-dione
C16H21NO2
Acta Crystallographica Section E (2013) 69, 12 o1801
a=20.266(4)Å b=4.69250(10)Å c=15.7807(11)Å
α=90.00° β=108.941(18)° γ=90.00°
Ethyl 2-{5-[(3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-4-yl)methyl]-1<i>H</i>-1,2,3-triazol-1-yl}acetate
C15H16N4O3S
Acta Crystallographica Section E (2014) 70, 2 o116
a=5.6414(2)Å b=11.1604(4)Å c=13.3724(5)Å
α=73.823(2)° β=87.226(2)° γ=88.566(2)°
3-Hexadecyl-1,5-dimethyl-1<i>H</i>-1,5-benzodiazepine- 2,4(3<i>H</i>,5<i>H</i>)-dione
C27H44N2O2
Acta Crystallographica Section E (2011) 67, 5 o1155
a=8.14260(10)Å b=36.2705(5)Å c=9.40900(10)Å
α=90.00° β=114.6110(10)° γ=90.00°
1-Octyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C15H22N2O
Acta Crystallographica Section E (2012) 68, 5 o1276
a=14.8888(18)Å b=5.8395(6)Å c=16.6778(19)Å
α=90.00° β=91.448(3)° γ=90.00°
(3<i>R</i>,4<i>S</i>)-3,4,8-Trihydroxy-1,2,3,4-tetrahydronaphthalen-1-one monohydrate
C10H10O4,H2O
Acta Crystallographica Section E (2012) 68, 6 o1874
a=4.6430(4)Å b=14.3904(11)Å c=14.4976(10)Å
α=90.00° β=90.00° γ=90.00°
1,1''-Bis(prop-2-en-1-yl)-1,1'',2,2''-tetrahydrodispiro[indole-3,7'- [6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C30H32N4O2
Acta Crystallographica Section E (2012) 68, 6 o1637
a=14.9484(2)Å b=9.91730(10)Å c=17.5713(3)Å
α=90.00° β=111.1190(10)° γ=90.00°
5,5''-Dibromo-1,1''-bis(prop-2-en-1-yl)-1,1'',2,2''-tetrahydrodispiro[indole- 3,7'-[6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C30H30Br2N4O2
Acta Crystallographica Section E (2012) 68, 6 o1638
a=14.1658(3)Å b=9.7203(2)Å c=20.6677(3)Å
α=90.00° β=100.0370(10)° γ=90.00°
4-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H16N4OS
Acta Crystallographica Section E (2014) 70, 2 o160-o161
a=13.283(2)Å b=5.3661(10)Å c=23.281(4)Å
α=90.00° β=96.633(10)° γ=90.00°
Ethyl 2-(2-amino-5-methyl-1,2,4-triazolo[1,5-<i>a</i>]pyrimidin-7-yl)acetate
C10H13N5O2
Acta Crystallographica Section E (2012) 68, 1 o239
a=22.9635(4)Å b=7.74470(10)Å c=14.7017(3)Å
α=90.00° β=124.5740(10)° γ=90.00°
5-Bromo-1-(prop-2-en-1-yl)-2,3-dihydro-1<i>H</i>-indole-2,3-dione
C11H8BrNO2
Acta Crystallographica Section E (2012) 68, 1 o240
a=31.3411(5)Å b=7.89950(10)Å c=8.27160(10)Å
α=90.00° β=90.00° γ=90.00°
3-{2-[(3-{(<i>E</i>)-2-[4-(Dimethylamino)phenyl]ethenyl}quinoxalin-2- yl)oxy]ethyl}-1,3-oxazolidin-2-one monohydrate
C23H24N4O3,H2O
Acta Crystallographica Section E (2012) 68, 1 o241
a=7.209800(10)Å b=23.3271(4)Å c=12.3994(2)Å
α=90.00° β=98.1190(10)° γ=90.00°
3-Hydroxy-4-phenyl-1-(prop-2-en-1-yl)-2,3,4,5-tetrahydro-1<i>H</i>- 1,5-benzodiazepin-2-one
C18H18N2O2
Acta Crystallographica Section E (2012) 68, 1 o238
a=51.6665(8)Å b=14.5766(2)Å c=11.9316(2)Å
α=90.00° β=90.965(2)° γ=90.00°
2-Phenylthieno[2,3-<i>b</i>]quinoxaline
C16H10N2S
Acta Crystallographica Section E (2012) 68, 2 o396
a=6.3875(3)Å b=16.2896(8)Å c=11.6054(6)Å
α=90.00° β=96.039(3)° γ=90.00°
1-(Prop-2-ynyl)-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C10H8N2O
Acta Crystallographica Section E (2013) 69, 1 o119
a=4.5553(6)Å b=18.001(3)Å c=10.7488(13)Å
α=90.00° β=93.645(8)° γ=90.00°
Bis[1-benzyl-2-(1,3-thiazol-4-yl)-1<i>H</i>-benzimidazole- κ^2^<i>N</i>^2^,<i>N</i>^3^]dichloridocobalt(II)
C34H26Cl2CoN6S2
Acta Crystallographica Section E (2013) 69, 1 m5-m6
a=10.1311(3)Å b=11.9582(4)Å c=14.2633(5)Å
α=76.033(3)° β=75.536(3)° γ=69.707(3)°
1-(4-Methylbenzyl)-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C15H14N2O
Acta Crystallographica Section E (2013) 69, 1 o122
a=12.5585(5)Å b=5.7181(2)Å c=17.4153(7)Å
α=90.00° β=95.277(2)° γ=90.00°
1-Benzyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C14H12N2O
Acta Crystallographica Section E (2011) 67, 7 o1822
a=13.8652(7)Å b=5.7975(3)Å c=14.9337(7)Å
α=90.00° β=109.5346(12)° γ=90.00°
Di-<i>tert</i>-butyl 2,6,11-trioxo-2,3-dihydro-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole-1,3-diacetate
C27H28N2O7
Acta Crystallographica Section E (2011) 67, 7 o1730
a=19.5785(4)Å b=13.0330(3)Å c=9.9269(2)Å
α=90.00° β=90.5830(10)° γ=90.00°
3-{[3-(4-Methoxyphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}- 1,5-dimethyl-1<i>H</i>-1,5-benzodiazepine-2,4(3<i>H</i>,5<i>H</i>)-dione
C22H23N3O4
Acta Crystallographica Section E (2011) 67, 7 o1729
a=28.0041(5)Å b=15.4644(3)Å c=9.0350(2)Å
α=90.00° β=93.2350(10)° γ=90.00°
5-Chloro-1-[(<i>E</i>)-3-(dimethylamino)acryloyl]-3-methyl-1<i>H</i>- benzimidazol-2(3<i>H</i>)-one--6-chloro-1-[(<i>E</i>)- 3-(dimethylamino)acryloyl]-3-methyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one (4/1)
C13H14ClN3O2
Acta Crystallographica Section E (2011) 67, 7 o1853
a=7.3145(2)Å b=14.2903(3)Å c=25.1512(6)Å
α=90.00° β=90.00° γ=90.00°
2-(3<i>H</i>-1,3-Benzothiazol-2-ylidene)propanedial
C10H7NO2S
Acta Crystallographica Section E (2011) 67, 9 o2260
a=8.3927(10)Å b=5.0972(8)Å c=20.739(2)Å
α=90.00° β=100.098(8)° γ=90.00°
2-[3-(1<i>H</i>-Benzimidazol-2-yl)propyl]-1-decyl-1<i>H</i>-benzimidazole
C27H36N4
Acta Crystallographica Section E (2011) 67, 9 o2544
a=38.5580(6)Å b=13.2052(2)Å c=9.9623(2)Å
α=90.00° β=95.3390(10)° γ=90.00°
4-(1,3-Benzothiazol-2-yl)-1,5-dimethyl-2-phenyl-1<i>H</i>-pyrazol- 3(2<i>H</i>)-one
C18H15N3OS
Acta Crystallographica Section E (2011) 67, 10 o2700
a=8.7428(2)Å b=25.7551(5)Å c=6.96600(10)Å
α=90.00° β=97.4600(10)° γ=90.00°
6-Bromoimidazo[1,2-<i>a</i>]pyridin-8-amine
C7H6BrN3
Acta Crystallographica Section E (2011) 67, 11 o2838
a=15.1378(5)Å b=21.2006(8)Å c=6.9744(3)Å
α=90.00° β=92.6106(7)° γ=90.00°
1,3-Dibenzyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C21H18N2O
Acta Crystallographica Section E (2011) 67, 12 o3234
a=19.5983(7)Å b=9.0882(2)Å c=10.0473(3)Å
α=90.00° β=115.593(4)° γ=90.00°
5-Chloro-1-nonyl-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C16H23ClN2O
Acta Crystallographica Section E (2011) 67, 12 o3340-o3341
a=5.51441(17)Å b=15.6507(4)Å c=20.0540(6)Å
α=71.807(3)° β=86.612(2)° γ=80.709(2)°
5-Acetyl-3-hydroxy-4-phenyl-4,5-dihydro-1<i>H</i>-1,5-benzodiazepin- 2(3<i>H</i>)-one
C17H16N2O3
Acta Crystallographica Section E (2011) 67, 12 o3337
a=8.97100(10)Å b=9.31420(10)Å c=9.41290(10)Å
α=81.5630(10)° β=68.9210(10)° γ=80.1460(10)°
3-Bromo-6-nitro-1-(prop-2-ynyl)-1<i>H</i>-indazole
C10H6BrN3O2
Acta Crystallographica Section E (2011) 67, 12 o3260
a=14.6573(3)Å b=4.16500(10)Å c=17.4566(3)Å
α=90.00° β=102.6590(10)° γ=90.00°
1-Benzyl-3-methyl-3',5'-diphenylspiro[quinoxaline-2(1<i>H</i>),2'(3'<i>H</i>)- 1,3,4-thiadiazole]
C29H24N4S
Acta Crystallographica Section E (2012) 68, 1 o103
a=13.5441(2)Å b=14.8971(2)Å c=15.0149(2)Å
α=66.4310(10)° β=63.9210(10)° γ=65.2750(10)°
5-Nitro-1-(prop-2-yn-1-yl)-2,3-dihydro-1<i>H</i>-1,3-benzodiazol-2-one
C10H7N3O3
Acta Crystallographica Section E (2012) 68, 4 o1240
a=7.2541(2)Å b=10.0362(2)Å c=14.6793(3)Å
α=100.9780(10)° β=92.0470(10)° γ=109.0430(10)°
1-Allyl-1<i>H</i>-1,3-benzimidazol-2(3<i>H</i>)-one
C10H10N2O
Acta Crystallographica Section E (2012) 68, 11 o3212
a=10.2749(5)Å b=5.5787(3)Å c=16.6220(9)Å
α=90.00° β=100.976(4)° γ=90.00°
1-Dodecyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one
C19H30N2O
Acta Crystallographica Section E (2012) 68, 11 o3069
a=38.3223(14)Å b=4.8318(2)Å c=21.9831(8)Å
α=90.00° β=117.843(2)° γ=90.00°
1-Allyl-6-nitro-1<i>H</i>-indazole
C10H9N3O2
Acta Crystallographica Section E (2012) 68, 12 o3368
a=4.3630(16)Å b=8.3245(7)Å c=13.541(5)Å
α=95.647(2)° β=98.46(2)° γ=97.770(2)°
1-Allyl-5-nitro-1<i>H</i>-benzimidazol-2(3<i>H</i>)-one
C10H9N3O3
Acta Crystallographica Section E (2013) 69, 3 o431
a=8.3246(3)Å b=14.9567(6)Å c=16.4461(7)Å
α=90.00° β=90.00° γ=90.00°
1-[(1-Benzyl-1<i>H</i>-1,2,3-triazol-4-yl)methyl]indoline-2,3-dione
C18H14N4O2
Acta Crystallographica Section E (2014) 70, 5 o588
a=11.53860(18)Å b=5.38700(9)Å c=23.2433(4)Å
α=90.00° β=92.1048(16)° γ=90.00°
Bis(1-benzyl-1<i>H</i>-benzimidazole-κ<i>N</i>^3^)dichloridozinc
C28H24Cl2N4Zn
Acta Crystallographica Section E (2014) 70, 3 m94-m95
a=9.9819(4)Å b=10.0564(4)Å c=13.6641(6)Å
α=99.539(2)° β=92.087(2)° γ=99.122(2)°
3-[2-(3-Phenyl-2-oxo-1,2-dihydroquinoxalin-1-yl)ethyl]-1,3-oxazolidin-2-one
C19H17N3O3
Acta Crystallographica Section E (2013) 69, 5 o662
a=9.6314(5)Å b=16.6596(9)Å c=10.0749(5)Å
α=90.00° β=98.097(3)° γ=90.00°
7-Chloro-5-methyl-2-phenylpyrazolo[1,5-<i>a</i>]pyrimidine
C13H10ClN3
Acta Crystallographica Section E (2013) 69, 5 o749
a=6.5993(2)Å b=12.6166(4)Å c=13.8702(5)Å
α=90.00° β=100.131(2)° γ=90.00°
<i>N</i>-(2-Bromo-4-methylphenyl)-2-(5-methyl-2-phenylpyrazolo[1,5-<i>a</i>]pyrimidin-7-yl)acetamide
C22H19BrN4O
Acta Crystallographica Section E (2013) 69, 6 o829
a=9.8102(6)Å b=7.2915(4)Å c=27.0162(14)Å
α=90.00° β=92.942(3)° γ=90.00°
Ethyl 2-oxo-3-(3-phthalimidopropyl)-2,3-dihydro-1<i>H</i>-1,3-benzimidazole-1-carboxylate
C21H19N3O5
Acta Crystallographica Section E (2013) 69, 5 o641-o642
a=5.2850(7)Å b=10.6663(12)Å c=16.505(2)Å
α=86.454(7)° β=83.424(8)° γ=89.376(7)°
Ethyl 7-methyl-2-phenylpyrazolo[1,5-<i>a</i>]pyrimidine-5-carboxylate
C16H15N3O2
Acta Crystallographica Section E (2013) 69, 5 o740
a=8.0542(8)Å b=16.4104(19)Å c=21.635(2)Å
α=90.00° β=90.00° γ=90.00°
3-Benzyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C13H10BrN3O
Acta Crystallographica Section E (2013) 69, 6 o962
a=4.2399(2)Å b=10.4463(4)Å c=14.5144(6)Å
α=107.611(2)° β=90.628(3)° γ=99.784(3)°
1-(Prop-2-en-1-yl)-3-{[3-(pyridin-4-yl)-4,5-dihydroisoxazol-5-yl]methyl}-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole-2,6,11(3<i>H</i>)-trione
C27H20N4O4
Acta Crystallographica Section E (2013) 69, 6 o945-o946
a=8.0930(2)Å b=12.1191(3)Å c=12.2743(2)Å
α=87.1090(10)° β=73.6120(10)° γ=72.2830(10)°
6-Bromo-1,3-bis[(1,3-dioxolan-2-yl)methyl]-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C14H16BrN3O5
Acta Crystallographica Section E (2013) 69, 7 o1029-o1030
a=5.11440(10)Å b=17.8029(4)Å c=16.5365(5)Å
α=90.00° β=97.009(2)° γ=90.00°
<i>N</i>'-Phenyl-<i>N</i>'-[3-(2,4,5-triphenyl-2,5-dihydro-1<i>H</i>-pyrazol-3-yl)quinoxalin-2-yl]benzohydrazide
C42H32N6O
Acta Crystallographica Section E (2013) 69, 8 o1320-o1321
a=12.0127(3)Å b=19.4679(5)Å c=15.2083(4)Å
α=90.00° β=106.0450(10)° γ=90.00°
<i>N</i>'-(3-Sulfanylidene-3,4-dihydroquinoxalin-2-yl)benzohydrazide dimethylformamide monosolvate
C15H12N4OS,C3H7NO
Acta Crystallographica Section E (2013) 69, 8 o1268
a=10.4053(2)Å b=16.8563(5)Å c=10.3624(2)Å
α=90.00° β=100.882(2)° γ=90.00°
3-(2,3-Dioxoindolin-1-yl)propanenitrile
C11H8N2O2
Acta Crystallographica Section E (2014) 70, 3 o361-o362
a=7.1967(2)Å b=9.9909(3)Å c=13.5534(5)Å
α=77.508(3)° β=81.551(3)° γ=77.717(3)°
4-[(1-Benzyl-1,2,3-triazol-5-yl)methyl]-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H16N4OS
Acta Crystallographica Section E (2014) 70, 3 o363-o364
a=34.5438(15)Å b=6.0102(2)Å c=15.6138(7)Å
α=90.00° β=90.00° γ=90.00°
(2<i>Z</i>)-2-Benzylidene-4-(prop-2-yn-1-yl)-2<i>H</i>-1,4-benzothiazin-3(4<i>H</i>)-one
C18H13NOS
Acta Crystallographica Section E (2014) 70, 5 o614
a=9.0254(13)Å b=7.7388(12)Å c=42.488(7)Å
α=90.00° β=90.00° γ=90.00°
1-Ethylpyrazolo[3,4-<i>d</i>]pyrimidine-4(5<i>H</i>)-thione
C7H8N4S
Acta Crystallographica Section E (2014) 70, 9 o1005-o1006
a=4.472(4)Å b=5.353(4)Å c=17.573(12)Å
α=90.00° β=93.71(4)° γ=90.00°
4-Allylsulfanyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine
C8H8N4S
Acta Crystallographica Section E (2014) 70, 9 o1038
a=18.537(6)Å b=5.1997(17)Å c=19.059(7)Å
α=90.00° β=90.00° γ=90.00°
2-(Benzylsulfanyl)-4-phenyl-3<i>H</i>-1,5-benzodiazepine
C22H18N2S
Acta Crystallographica Section E (2007) 63, 7 o3305-o3305
a=8.9633(2)Å b=8.4904(2)Å c=23.1997(5)Å
α=90.00° β=92.2060(10)° γ=90.00°
1,3-Dibenzyl-6-bromo-1<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-2(3<i>H</i>)-one
C20H16BrN3O
Acta Crystallographica Section E (2010) 66, 4 o754
a=9.16270(10)Å b=25.5071(3)Å c=8.06290(10)Å
α=90.00° β=115.5710(10)° γ=90.00°
1,3-Diallyl-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole-2,6,11(3<i>H</i>)-trione
C21H16N2O3
Acta Crystallographica Section E (2010) 66, 7 o1851
a=7.8539(2)Å b=11.5822(3)Å c=18.1455(4)Å
α=90.00° β=93.5370(10)° γ=90.00°
1,3-Bis(naphthalen-2-ylmethyl)-1<i>H</i>-anthra[1,2-<i>d</i>]imidazole- 2,6,11(3<i>H</i>)-trione
C37H24N2O3
Acta Crystallographica Section E (2011) 67, 8 o2138
a=8.09010(10)Å b=12.8226(2)Å c=26.1472(4)Å
α=90.00° β=90.00° γ=90.00°
7-phenyl-1,4-diazepin-5-one monohydrate
C11H14N2O2
Zeitschrift für Kristallographie - New Crystal Structures (2001) 216, 1 101-102
a=7.1014(4)Å b=8.6896(7)Å c=10.1265(8)Å
α=70.175(3)° β=88.517(5)° γ=66.283(4)°
C24H34Cl2N8O12Zn0.5
C24H34Cl2N8O12Zn0.5
Zeitschrift für Kristallographie - New Crystal Structures (2001) 216, 4 635-636
a=15.7901(6)Å b=11.5163(4)Å c=20.1992(6)Å
α=90.000(1)° β=154.373(3)° γ=90.000(1)°